Maria Paola Costi
SEEK ID: https://fairdomhub.org/people/1969
Location:
Italy
ORCID:
https://orcid.org/0000-0002-0443-5402
Joined: 30th Mar 2021
Expertise: Not specified
Tools: Not specified
Roles
Project administrator
- NMTrypI - New Medicines for Trypanosomatidic Infections
- Mass spectrometry proteomics for biomarker discovery
- Thymidylate synthase dimer dissociation
Programme administrator
Their tagsRelated items
The recent COVID19 pandemic infection has undisclosed long-standing issues in the translation of drugs from animals to humans or vice-versa. Nearly 75% of emerging human infections worldwide originated from animals; existing drugs for human and animal (H&A) vector-borne diseases (VBD) are scarce, with limited efficacy, toxicity, and finite resources. Emerging environmental problems in pharmaceutical use/manufacturing increase attention in the field. The two drug pipelines are developed ...
Projects: WG1 - Compound libraries coordination and integration of compound design, WG2 - Integration of early phase studies and low environmental impact actions, WG3 - Coordination of in vitro-to-in vivo translation of OneHealth leads and candidates, WG4 - Integration of R&D process-environmental studies and translation in informed whitepaper, WG5 - Promote dissemination, WG6 - Promote the transfer of knowledge, BioTarget Database, Compound Data
Web page: https://onehealthdrugs.com/
Projects: Mass spectrometry proteomics for biomarker discovery, TEAD-(YAP) structure, function and inhibition, Thymidylate synthase dimer dissociation
Web page: Not specified
Projects: NMTrypI - New Medicines for Trypanosomatidic Infections
Web page: https://cordis.europa.eu/programme/id/FP7_HEALTH.2013.2.3.4-2
Public web page: Not specified
Public web page: Not specified
The New Medicines for Trypanosomatidic Infections - NMTrypI project aimed at obtaining new candidate drugs against Trypanosomatidic infections with appropriate efficiency from the lead phase to the final preclinical phase that are more accessible to patients.
Programme: Drug development for neglected parasitic diseases
Public web page: https://fp7-nmtrypi.eu/
Start date: 1st Feb 2014
End date: 31st Jan 2017
Programme: Cancer drug discovery preclinical research
Public web page: Not specified
Programme: Cancer drug discovery preclinical research
Public web page: Not specified
Semi-targeted Mass Spectrometry proteomics study to detect 12 selected proteins of two serum samples belonging to the FOLFOX-4 study on heavly-pretreated ovarian cancer patients. The two samples, F10 and F12, are basal samples collected at before the first FOLFOX-4 treatment cycle (T0) and were selected for this study because they show a different proteome profile.
Download
Supplementary material for "Mass spectrometry proteomic and network enrichment analysis to track FOLFOX response in drug resistant ovarian carcinoma"
